Trial reportCancer imaging : the official publication of the International Cancer Imaging Society2016
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Trial report in Cancer imaging : the official publication of the International Cancer Imaging Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- ESR Essentials: response assessment criteria in oncologic imaging-practice recommendations by the European Society of Oncologic Imaging.European radiology · 2025Guideline
- Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.Frontiers in oncology · 2021Pooled it
- Calibration phantom-based prediction of CT lung nodule volume measurement performance.Quantitative imaging in medicine and surgery · 2023Article
- RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment.Radiology. Imaging cancer · 2023Article
- Radiomic and Volumetric Measurements as Clinical Trial Endpoints-A Comprehensive Review.Cancers · 2022Review
- Radiomics/Radiogenomics in Lung Cancer: Basic Principles and Initial Clinical Results.Cancers · 2022Review
- Tumor Growth Rate After Nadir Is Associated With Survival in Patients WithJCO precision oncology · 2021Article
- Radiomics in lung cancer for oncologists.Journal of clinical and translational research · 2020Article
- Tumor volume dynamics and tumor growth rate inEuropean journal of radiology open · 2020Article
- Review
- Clustering approach to identify intratumour heterogeneity combining FDG PET and diffusion-weighted MRI in lung adenocarcinoma.European radiology · 2019Article
- Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival.JCO clinical cancer informatics · 2018Article
- Article
- Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2018Review
- Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment.PLoS computational biology · 2017Article
- The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aim to determine whether volumetric assessment has the potential to serve as a prognostic biomarker, and to assess the relationship between longitudinal tumor data during treatment and prognosis in lung adenocarcinoma patients with sensitizing EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKI).
methodsWe retrospectively assessed patients with EGFR-mutant stage IV lung adenocarcinoma who were treated with EGFR TKIs until disease progression. CT studies of 106 patients were quantitatively analyzed in terms of tumor size and volume by comparing baseline and follow-up CT scans obtained at every two treatment cycles. Tumor response was quantified using longitudinal measurements, and tumor growth kinetics was determined. Correlation with early surrogate parameters for tumor response evaluation such as change in size, volume, and response rate was performed. The Cox-proportional hazard model and Log-rank test were used to predict overall survival (OS).
resultsResponders based on the percent change in volume after four cycles of TKI therapy had a higher OS than non-responders (P = 0.035). The percent of volume and size changes after four cycles of TKI therapy were significantly correlated with TTP (P < 0.001).
conclusionVolume measurements and corresponding rates of growth appear to be helpful adjuncts for predicting survival in patients undergoing EGFR-TKI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.